Shipping Now

Rapid, accurate diagnostics. Anywhere, anytime.

The Clip COVID-19 rapid antigen test is the most accurate FDA authorized point-of-care test on the market with 100% NPA/Specificity and 96.9% PPA/Sensitivity and automated API-connected result integrations.*

*Data Source: AdVeritasDx Test Database

With Clip Health, we’ve created a turnkey testing solution that streamlines our antigen testing by automatically integrating test results with our patient registration & reporting software within seconds. Because we screen such a high volume of patients for employer compliance and for events, results integration simplifies our logistics enormously and helps our technicians reduce error and save time.
Andreas M. Kogelnik, MD, PhD
Chief Executive Officer
BasisDx

The Clip COVID test is among the most accurate FDA-authorized rapid antigen tests available on the market, with 100% specificity and 96.9% sensitivity. In addition, the Clip Analyzer’s intuitive app interface and on-screen instructions make it easy to access reliable, actionable health data fast. Clip Health’s rapid, accurate COVID-19 tests are a welcome addition to our mobile healthcare solutions, testing
anywhere, anytime.
Randall Sosnick
Chief Executive Officer
Lookout Health

Our customers rely on us to provide them with state-of-the-art patient registration and resulting software to streamline their testing experience. Clip Health is the only rapid test provider that aligns with our vision of a tech-forward and streamlined user experience with their automatic test results integration. We value a partnership that provides the best experience for our customers.
Lee Springer, PhD
Director of Laboratory Partnerships
Brio Systems

We empower you with access to reliable, actionable health data, fast.

COVID-19 + Flu Test

15-minute Rx home use test

Detection and differentiation of SARS-CoV-2, influenza A, and influenza B antigens from a self-collected nasal swab. Readout using the re-usable Core analyzer connected to the Clip Health iOS/Android app.

*In late development, pending FDA EUA submission

Covid 19

COVID-19 Point-of-Care Test

30-minute point-of-care antigen test

EUA-authorized. Detection of SARS-CoV-2 nucleocapsid protein from anterior nose swab. Verified to detect the delta variant in symptomatic and asymptomatic individuals. Readout using Clip Analyzer, an iPhone-connected analyzer for high-volume point-of-care use.

Our product vision is to enable accessible, personalized, and actionable health testing, with immediate follow-up, across infectious, metabolic, endocrine, and chronic diseases and conditions.
Learn more

Our Platform

The Clip hardware and software leverage patented innovations in nanotechnology, materials chemistry, and signal processing to enable high-accuracy, cost-effective diagnostics.

Clip Analyzer

Core

Who we are

Clip Health is a health-tech company with a mission of increasing healthcare accessibility and efficiency by designing, developing, manufacturing, and delivering products and services that enable affordable, widespread access to actionable health testing with immediate follow-up.

Want to join the team? We’re hiring.
See all open positions

Crew outdoors

Company News

Emergency Use Authorization (EUA) Disclaimer

© 2021 Luminostics, Inc. dba Clip Health In the USA, the Clip COVID Rapid Antigen Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for emergency use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet the requirements to perform high, moderate, or waived complexity tests. This test is for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. In the USA, the emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.